Type Public Number of employees 215 (April 30, 2015) Founded 1981 Total equity 97.65 million USD (2015) | Industry Pharmaceuticals Revenue 26.78 million USD (2015) Total assets 97.46 million USD (2015) | |
 | ||
Traded as NASDAQ: PPHM,NASDAQ: PPHMP Key people Steven W. King
(President and CEO) Operating income Net income US$ -50.358 million (2015) Stock price PPHM (NASDAQ) US$ 0.71 +0.03 (+4.33%)24 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Tustin, California, United States | ||
Peregrine Pharmaceuticals, Inc. is a publicly-traded American biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials as potential cancer treatments and diagnostic agents. As of 2016 their lead product candidate was bavituximab. It also has a revenue-generating subsidiary, Avid Bioservices, which is a contract manufacturing organization that provides services to Peregrine and to other companies.
Contents
Peregrine pharmaceuticals inc pphm stock chart technical analysis for 02 27 17
History
Peregrine was founded in 1981.
In 2002 Peregrine established a wholly owned subsidiary, Avid Bioservices, a contract manufacturing organization that provides cGMP development and biomanufacturing services for both Peregrine and outside customers. In 2015 Avid had revenues of about $27 million, about 80% of which came under contract from Halozyme Therapeutics.
Bavituximab
Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C. The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans.
124I-PGN650
124I-PGN650 is a phosphatidylserine-targeting F(ab')2 fully human monoclonal antibody fragment joined to the PET imaging radio-isotope iodine-124 being developed to obtain medical images of cancer.
Cotara
Cotara (131I-chTNT-1/B) is a chimeric monoclonal antibody against DNA-histone H1 complex called TNT-1, conjugated to the radioisotope iodine-131. As of 2016 Peregrine was developing it for Glioblastoma multiforme; it has been granted orphan status in Europe and the US.